Abhimanyu Verma Sells 2,519 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 2,519 shares of the business’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $4.86, for a total transaction of $12,242.34. Following the sale, the chief technology officer owned 205,430 shares of the company’s stock, valued at $998,389.80. This represents a 1.21% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $5,016.10.

SOPHiA GENETICS Stock Down 0.3%

Shares of NASDAQ:SOPH traded down $0.01 during trading on Wednesday, hitting $4.89. 64,929 shares of the company were exchanged, compared to its average volume of 188,371. The stock has a market capitalization of $334.64 million, a P/E ratio of -9.58 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.96 and a quick ratio of 1.84. SOPHiA GENETICS SA has a 12-month low of $2.58 and a 12-month high of $5.70. The firm’s 50 day moving average price is $4.78 and its 200-day moving average price is $4.68.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to analysts’ expectations of $21.20 million. SOPHiA GENETICS had a negative return on equity of 50.60% and a negative net margin of 44.22%. On average, research analysts predict that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Institutional Trading of SOPHiA GENETICS

Institutional investors and hedge funds have recently bought and sold shares of the business. Savvy Advisors Inc. purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $48,000. Squarepoint Ops LLC purchased a new stake in SOPHiA GENETICS in the 3rd quarter valued at $49,000. Perkins Capital Management Inc. purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at $49,000. Quadrature Capital Ltd purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at $54,000. Finally, XTX Topco Ltd purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Thursday, January 22nd. BTIG Research reiterated a “buy” rating and issued a $7.00 price target on shares of SOPHiA GENETICS in a research report on Tuesday, March 3rd. Finally, Guggenheim upped their price target on shares of SOPHiA GENETICS from $6.00 to $7.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $7.00.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.